Last reviewed · How we verify
Bravecto (FLURALANER)
Bravecto (fluralaner) is a small molecule medication originally developed by Intervet and currently owned by Merck Animal Health. It is used to treat flea and tick infestations in dogs and cats. Bravecto works by inhibiting the nervous system of fleas and ticks, ultimately leading to their death. It is FDA approved for use in the United States and is available in both patented and generic forms. Key safety considerations include potential side effects such as vomiting, diarrhea, and lethargy.
At a glance
| Generic name | FLURALANER |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
- Lethargy
- Decreased appetite
- Vomiting
- Diarrhea
- Liver enzymes (serum ALT or ALP) greater than twice the upper reference range
- Pruritus
- Injection site lumps or swelling
Serious adverse events
- Seizures
- Anaphylaxis
- Immune-mediated hemolytic anemia
- Hypersensitivity reactions
- Acute hemorrhagic diarrhea syndrome
- Ataxia
- Tremors
- Injection site abscess
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bravecto CI brief — competitive landscape report
- Bravecto updates RSS · CI watch RSS